Annual report pursuant to Section 13 and 15(d)

Income Taxes (Narrative) (Details)

v3.20.2
Income Taxes (Narrative) (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 01, 2020
Mar. 31, 2020
Aug. 31, 2020
Jul. 31, 2020
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Expense (Benefit) [Line Items]                  
Corporate income tax rate           21.00% 21.00% 21.00% 35.00%
Income tax refund     $ 500,000            
Deferred tax asset, change in small business status         $ 900,000 $ 900,000      
Income tax benefit           (1,078,441) $ (303,933)    
Deferred tax liabilities, in process research and development             4,100,000    
Impairment of intangible assets         14,100,000 14,100,000      
Change in valuation allowance           3,200,000      
Unrecognized tax benefits         0 0 0    
Penalties and interest expense           0 0    
United Kingdom [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Corporate income tax rate   19.00%   19.00%          
Income tax benefit           $ 1,300,000      
Scenario, Plan [Member] | United Kingdom [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Corporate income tax rate 17.00%                
Alternative Minimum Tax [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Prepaid taxes             500,000    
Minimum [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Operating loss carryforwards, expiration date           Dec. 31, 2022      
Maximum [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Operating loss carryforwards, expiration date           Dec. 31, 2038      
Domestic [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Operating loss carryforwards         41,700,000 $ 41,700,000      
Domestic [Member] | 2022 to 2038 [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Operating loss carryforwards         13,500,000 13,500,000      
Domestic [Member] | Indefinite [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Operating loss carryforwards         28,200,000 28,200,000      
State [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Operating loss carryforwards         25,700,000 25,700,000      
State [Member] | 2022 to 2038 [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Operating loss carryforwards         19,800,000 19,800,000      
State [Member] | Indefinite [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Operating loss carryforwards         5,900,000 5,900,000      
Foreign [Member] | Indefinite [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Operating loss carryforwards         61,300,000 61,300,000      
United States [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Valuation allowance         11,700,000 11,700,000 7,600,000    
U.K. [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Valuation allowance, deferred tax asset, change in amount           4,100,000      
U.K. [Member] | The Female Health Company Limited [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Valuation allowance         2,400,000 2,400,000      
Acquired In-Process Research and Development [Member]                  
Income Tax Expense (Benefit) [Line Items]                  
Intangible assets, net         $ 3,900,000 $ 3,900,000 $ 18,000,000